Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101

The phase 3 JAVELIN Renal 101 trial of avelumab + axitinib vs sunitinib in patients with treatment‐naive advanced renal cell carcinoma (RCC) demonstrated significantly improved progression‐free survival (PFS) and higher objective response rate (ORR) with the combination vs sunitinib. Japanese patien...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Uemura, Motohide, Tomita, Yoshihiko, Miyake, Hideaki, Hatakeyama, Shingo, Kanayama, Hiro‐omi, Numakura, Kazuyuki, Takagi, Toshio, Kato, Tomoyuki, Eto, Masatoshi, Obara, Wataru, Uemura, Hirotsugu, Choueiri, Toni K., Motzer, Robert J., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, di Pietro, Alessandra, Oya, Mototsugu
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060483/
https://ncbi.nlm.nih.gov/pubmed/31883418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14294
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares